Biogen Idec, Roche To Stop Ocrelizumab’s Rheumatoid Arthritis Trial – Update – RTT News
By Dr. Matthew Watson
 Earthtimes (press release) | Biogen Idec, Roche To Stop Ocrelizumab's Rheumatoid Arthritis Trial - Update RTT News (RTTNews) - Biotechnology company Biogen Idec Inc. (BIIB: News ) and its Swiss peer Roche Holding AG (RHHBY.PK: News ) Wednesday stated that they decided to ... Roche, Biogen end arthritis drug developmentReuters |
Uncategorized
Comments Off on Biogen Idec, Roche To Stop Ocrelizumab’s Rheumatoid Arthritis Trial – Update – RTT News |
May 19th, 2010
This author published 6052 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research